Wall Street Zen downgrades NovoCure stock to Hold

Published on 10/15/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NovoCure reported USD 183.58 million in second-quarter revenue, up 15.60 percent year over year. NovoCure stock costs EUR 12.33 on October 15, 2026.

Approval and earnings guide the stock

Japan approved Optune Pax on October 1, 2026, with 76.30 percent of trial participants experiencing device-related skin events.
Wall Street Zen moved to Hold on October 10, 2026, while MarketBeat cited a USD 21.20 average target.
NovoCure stock traded at EUR 12.33 at 1:00 p.m. CEST at Lang & Schwarz on October 15, 2026.

NVCR, JE00BYSS4X48, Illustration mit AI erstellt.

NovoCure (JE00BYSS4X48) stock traded at EUR 12.33 at Lang & Schwarz on October 15, 2026 at 1:00 p.m. CEST. MarketBeat reported on October 10, 2026 that Wall Street Zen downgraded NovoCure from Buy to Hold.

Japan approval expands reach

Japan's Ministry of Health, Labour and Welfare approved Optune Pax for unresectable locally advanced pancreatic cancer on October 1, 2026. The Business Wire release said the approval followed the Phase 3 PANOVA-3 trial, in which 76.30 percent of treated participants experienced device-related skin adverse events.

What does Q2 mean for margins?

NovoCure's second-quarter revenue reached USD 183.58 million for the period ended June 30, 2026, up 15.60 percent from a year earlier, according to Yahoo Finance. Adjusted EBITDA was USD 11.00 million, compared with negative USD 10.00 million in the second quarter of 2025, while full-year revenue guidance stood at USD 710.00 million to USD 725.00 million.

Three events shape the story

On July 23, 2026, NovoCure reported USD 183.58 million in second-quarter revenue. On October 1, 2026, Japan approved Optune Pax for pancreatic cancer. On October 10, 2026, Wall Street Zen moved its rating from Buy to Hold, while MarketBeat cited an average price target of USD 21.20.

Dates for the next catalyst

BioSpace reported that NovoCure will publish third-quarter 2026 results on October 29, 2026, before the U.S. markets open. The company scheduled its earnings conference call for 8:00 a.m. EDT on the same date.

Stock price and valuation context

NovoCure is an oncology company developing and commercializing Tumor Treating Fields devices, including Optune Gio, Optune Lua and Optune Pax. The company had a market capitalization of USD 1.6 billion as of October 15, 2026, while its Nasdaq listing and NVCR ticker were identified in company and market materials. NovoCure's next major test is whether the Japan launch and improving adjusted EBITDA can support the revenue guidance ahead of the October 29 results.

NovoCure was trading at EUR 12.33 at Lang & Schwarz on October 15, 2026 at 1:00 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of NovoCure stock.